Literature DB >> 18179674

Economic burden of adult pharyngitis: the payer's perspective.

Alan R Salkind1, Julie M Wright.   

Abstract

OBJECTIVES: Although not recommended by practice guidelines, physicians frequently prescribe an antibiotic for adults with viral pharyngitis. The financial burden of this practice, from the payer's perspective, has not been previously evaluated. The purpose of this study was to estimate those expenditures.
METHODS: A cost-of-illness study was performed to estimate annual expenditures of pharyngitis management from the payer's perspective. National Ambulatory Care Survey data were used to represent current patterns of ambulatory care visits and antibiotic prescriptions for adult pharyngitis. Direct and antibiotic resistance costs were summed to estimate total expenditures for pharyngitis management. Resistance costs were calculated using a model linking the effect of antibiotic consumption to the cost consequences of resistant Streptococcus pneumoniae infection. Sensitivity analyses compared cost outcomes of current practice, adherence to pharyngitis management guidelines from the Infectious Diseases Society of America (IDSA), and nonantibiotic treatment.
RESULTS: In the base-case analysis, reflecting current practice patterns, total expenditures were $1.2 billion with antibiotic resistance contributing 36% ($426 million). IDSA guideline adherence decreased costs to $559 million with resistance accounting for 6.8% ($37.9 million). Guideline adherence plus reducing office visits by 30% decreased costs to $372 million, with only 1.4% ($5.3 million) due to resistance. Additional cost-savings of $88 million were realized by using a nonantibiotic treatment strategy.
CONCLUSIONS: Current practice imposed a substantial economic burden on the payer, while guideline adherence resulted in cost reductions, especially in terms of resistance, emphasizing that antibiotic prescribing habits have broad economic consequences. Relevant stakeholders, payers, physicians, and other health-care providers should revisit efforts to encourage adherence to pharyngitis guidelines to reduce health-care costs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18179674     DOI: 10.1111/j.1524-4733.2007.00286.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  7 in total

1.  Measuring the externality of antibacterial use from promoting antimicrobial resistance.

Authors:  Klaus Kaier; Uwe Frank
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Management of adults with acute streptococcal pharyngitis: minimal value for backup strep testing and overuse of antibiotics.

Authors:  Georges N Nakhoul; John Hickner
Journal:  J Gen Intern Med       Date:  2012-10-06       Impact factor: 5.128

3.  Multicenter Clinical Evaluation of the Automated Aries Group A Strep PCR Assay from Throat Swabs.

Authors:  N Kanwar; J Crawford; C Ulen; T S Uphoff; J Dien Bard; R Dunn; A Drain; R Selvarangan
Journal:  J Clin Microbiol       Date:  2019-01-30       Impact factor: 5.948

4.  Equal performance of self-collected and health care worker-collected pharyngeal swabs for group a streptococcus testing by PCR.

Authors:  Martha A Murray; Lorie A Schulz; Joseph W Furst; Jason H Homme; Sarah M Jenkins; James R Uhl; Robin Patel; Franklin C Cockerill; Jane F Myers; Bobbi S Pritt
Journal:  J Clin Microbiol       Date:  2014-12-10       Impact factor: 5.948

5.  The NAtional randomised controlled Trial of Tonsillectomy IN Adults (NATTINA): a clinical and cost-effectiveness study: study protocol for a randomised control trial.

Authors:  Isabel Rubie; Catherine Haighton; James O'Hara; Nikki Rousseau; Nick Steen; Deborah D Stocken; Frank Sullivan; Luke Vale; Scott Wilkes; Janet Wilson
Journal:  Trials       Date:  2015-06-06       Impact factor: 2.279

6.  Kikyo-to vs. Placebo on Sore Throat Associated with Acute Upper Respiratory Tract Infection: A Randomized Controlled Trial.

Authors:  Naoto Ishimaru; Saori Kinami; Toshio Shimokawa; Yohei Kanzawa
Journal:  Intern Med       Date:  2019-06-07       Impact factor: 1.271

7.  Cost and effectiveness analysis of the diagnostic and therapeutic approaches of group A Streptococcus pharyngitis management in Iran.

Authors:  Zahra Behnamfar; Vahid Shahkarami; Sara Sohrabi; Amin Shafiee Aghdam; Hasan Afzali
Journal:  J Family Med Prim Care       Date:  2019-09-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.